Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

The safety and tolerability of AR101, an oral immunotherapy (OIT) pharmaceutical formulation for peanut allergy, after more than 1 year of treatment: results from an ongoing phase 2b clinical trial (ARC002), including low-dose (300 mg/day) and high-dose (2000 mg/day) maintenance regimens

R. A. Rachid,J. A. Bird,J. M. Spergel,S. M. Jones,A. H. Assa'ad,B. Vickery, J. Wang,S. A. Leonard,S. S. Laubach,E. H. Kim, B. P. Davis,M. J. Welch,J. Heimall,A. Cianferoni,A. J. MacGinnitie, E. Crestani, S. Bennett, R. M. Elfont,A. W. Burks

ALLERGY（2016）

Cited 0|Views14
No score
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined